These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32957414)

  • 1. The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol.
    Kainuma M; Funakoshi K; Ouma S; Yamashita KI; Ohara T; Yoshiiwa A; Murata M; Tsuboi Y
    Medicine (Baltimore); 2020 Sep; 99(38):e22370. PubMed ID: 32957414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease.
    Kainuma M; Ouma S; Kawakatsu S; Iritani O; Yamashita KI; Ohara T; Hirano S; Suda S; Hamano T; Hieda S; Yasui M; Yoshiiwa A; Shiota S; Hironishi M; Wada-Isoe K; Sasabayashi D; Yamasaki S; Murata M; Funakoshi K; Hayashi K; Shirafuji N; Sasaki H; Kajimoto Y; Mori Y; Suzuki M; Ito H; Ono K; Tsuboi Y
    Front Pharmacol; 2022; 13():991982. PubMed ID: 36313371
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial.
    Chua KK; Wong A; Kwan PW; Song JX; Chen LL; Chan AL; Lu JH; Mok V; Li M
    Trials; 2015 Apr; 16():199. PubMed ID: 25925312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
    Namiki T; Takayama S; Arita R; Ishii T; Kainuma M; Makino T; Mimura M; Yoshino T; Nogami T; Arai M; Sato J; Tanaka K; Nakae H; Igari H; Ozawa Y; Shiko Y; Kawasaki Y; Nezu M; Ito T
    Trials; 2021 Jan; 22(1):23. PubMed ID: 33407828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic changes in the plasma of mild Alzheimer's disease patients treated with Hachimijiogan.
    Kainuma M; Kawakatsu S; Kim JD; Ouma S; Iritani O; Yamashita KI; Ohara T; Hirano S; Suda S; Hamano T; Hieda S; Yasui M; Yoshiiwa A; Shiota S; Hironishi M; Wada-Isoe K; Sasabayashi D; Yamasaki S; Murata M; Funakoshi K; Hayashi K; Shirafuji N; Sasaki H; Kajimoto Y; Mori Y; Suzuki M; Ito H; Ono K; Tsuboi Y
    Front Pharmacol; 2023; 14():1203349. PubMed ID: 37377927
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial].
    Yu L; Lin SM; Zhou RQ; Tang WJ; Huang PX; Dong Y; Wang J; Yu ZH; Chen JL; Wei L; Xing SL; Cao HJ; Zhao HB
    Zhong Xi Yi Jie He Xue Bao; 2012 Jul; 10(7):766-76. PubMed ID: 22805083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of acupuncture and Chinese herbal formula for elderly adults with mild cognitive impairment: protocol for a randomized controlled trial.
    Chen Y; Zhang W; Wu H; Lao L; Xu J; Xu S
    Trials; 2019 Feb; 20(1):117. PubMed ID: 30744676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial.
    Miao YC; Tian JZ; Shi J; Mao M
    Zhong Xi Yi Jie He Xue Bao; 2012 Apr; 10(4):390-7. PubMed ID: 22500712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial.
    Fu QH; Pei J; Zhou HG; Wang T; Zhan YJ; Tao L; Xu J; Zhou Q; Wang LY
    Trials; 2022 Aug; 23(1):695. PubMed ID: 35986297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial.
    Yang Y; Liu JP; Fang JY; Wang HC; Wei Y; Cao Y; Liu JG; Liu LT; Li H
    Chin J Integr Med; 2019 Aug; 25(8):574-581. PubMed ID: 30109588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.